



ASX/MEDIA RELEASE

14 March 2018

## Update on Scheme of Arrangement

### Sydney, Australia

Sirtex Medical (ASX:SRX) (**Sirtex**) today announces that formal notification from both the US Federal Trade Commission (FTC) and the German Federal Cartel Office (FCO) on the proposed acquisition of all of the shares in Sirtex by Varian Medical Systems, Inc. (NYSE:VAR) by way of scheme of arrangement (**Scheme**) has been received.

The US FTC has granted early termination of the waiting period under the Clayton Act and Premerger Notification Rules with respect to the Scheme. The German FCO confirmed the proposed Scheme does not fulfil the conditions for prohibition pursuant to the Act Against Restraints of Competition.

Receipt of these approvals in respect of the Scheme were two of the key conditions to implementation of the Scheme.

A draft scheme booklet (**Scheme Booklet**) in relation to the Scheme was lodged with the Australian Securities and Investments Commission (**ASIC**) on Friday, 9 March 2018. Following review by ASIC and subject to the issuance of orders by the Federal Court of Australia approving despatch of the Scheme Booklet to Sirtex shareholders, the Scheme Booklet is expected to be despatched to Sirtex shareholders on or around Thursday, 5 April 2018.

– ENDS –

### About Sirtex Medical, [www.sirtex.com](http://www.sirtex.com)

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

#### Investor Enquiries:

Mr Andrew McLean  
CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

#### Investor/Media Enquiries:

Dr Tom Duthy  
Global Head of Investor Relations &  
Corporate Development  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

To subscribe to our email alert service for ASX Announcements, please visit:  
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**  
Visit us on LinkedIn: **Sirtex Medical Limited**